QTERN Dosage/Direction for Use

The recommended dose of Saxagliptin/Dapagliflozin (QTERN) is one saxagliptin 5 mg/dapagliflozin 10 mg tablet taken once daily at any time of the day, with or without food. Tablet is to be swallowed whole.
Special Populations: Patients with renal impairment: No dosage adjustment is recommended based on renal function.
Renal function should be evaluated prior to initiation of Saxagliptin/Dapagliflozin (QTERN) and periodically thereafter. Saxagliptin/Dapagliflozin (QTERN) should not be used in patients with an estimated glomerular filtration rate (eGFR) persistently < 45 mL/min/1.73m² as calculated by the Modification of Diet in Renal Disease (MDRD) formula or in patients with end-stage renal disease (ESRD) (see Precautions).
Patients with hepatic impairment: Saxagliptin/Dapagliflozin (QTERN) may be used in patients with hepatic impairment. The safety and efficacy of Saxagliptin/Dapagliflozin (QTERN) have not been specifically studied in patients with severe hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Paediatric and adolescent patients: Safety and effectiveness of Saxagliptin/Dapagliflozin (QTERN) in pediatric and adolescent patients (< 18 years of age) have not been established.
Geriatric patients: Because elderly patients are more likely to have decreased renal function, care should be taken in the elderly based on renal function (see Pharmacology: Pharmacodynamics under Actions).